Navigation Links
Diversified Pipeline and Low Threat of Biosimilar Sales Erosion To Drive Growth Of Monoclonal Antibodies Market

NEW YORK, LONDON, BERLIN, PARIS, March 19, 2013 /PRNewswire/ --

The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selling drugs. The unique density of monoclonal antibodies that are approved for this indication, significant market exclusivity expiries in the forecast period and yet more monoclonal antibodies in development will change the dynamics in and this highly lucrative market in the forecast period until 2018. A new report from the leading business intelligence provider states in their latest research titled, "Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018".

Scope of the Report

- The current therapeutic environment in the treatment of RA across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.

- Analysis of the competitive environment for monoclonal antibodies with strong data and evidence-based profiling of marketed products, including comparative benchmarking and assessment of efficacy and safety profiles as well as differentiating product features.

- A detailed pipeline analysis for monoclonal antibodies in rheumatoid arthritis including individual product profiles, a comparative efficacy and safety profile heat map analysis of the most promising pipeline products as well as analyses on the distribution of molecule types across the RA developmental pipeline, the molecular targets of pipeline mAbs and the developmental program types. In addition, detailed analyses of the clinical trial failure rates, the clinical trial durations by phase and clinical trial sizes by participant numbers are provided.

- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.

- Market forecasts across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan. The multiple scenario forecasts take a range of factors that are likely to vary into account and provide a clear perspective on the level of the potential degree of variance in the market sizes.

- Key market drivers and barriers

- The major deals that have taken place in the monoclonal antibodies market in rheumatoid arthritis in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and molecular targets is also provided.

Reasons to buy

- Understand the competitive environment for monoclonal antibodies

- Develop key strategic repositioning initiatives by studying the repositioning trends and strategies of current competitors

- Understand the clinical and commercial impact of the growing diversification of the molecular targets of monoclonal antibodies in the pipeline and identify potential first-in-class products

- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the RA market in the forecast period

- Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for monoclonal antibodies in RA

- Use key benchmark data to forecast costs of developmental programs for monoclonal antibodies in RA by using proprietary clinical trial size and duration analyses

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

- Use proprietary data analyses to assess the market value of pipeline molecules for in-licensing and out-licensing opportunities

To view the detailed table of contents of this report kindly click - Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 or copy and paste the following link in your browser:

Other Latest Pharma Market research reports:

Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential

MRI Systems Market to 2018 - Technological advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth

Arthroscopy Devices Market to 2018 - Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Future Growth

Partnering Deals and Alliances with Big Pharma

Bioinformatics Partnering Terms and Agreements

About Reportstack™: is one of the leading distributors of market research reports in the world today. provides access to over 50,000 company profiles and their strategic information like SWOT analysis, deals and partnerships analysis, merger & acquisition activity and new product launches. is also a leader in the field of Pharma partnership deals and competitor analysis and Medical Devices Research Reports.

Nathan Gold
Phone: +1-888-789-6604

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. iBio Adds to iBioModulator Portfolio and Product Pipeline
2. iBio Adds New Therapeutic Antibody to Its Pipeline
3. Renal Dialysis Equipment - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
4. Chemotherapy Induced Nausea and Vomiting (CINV) Existing and Pipeline Drugs Market is Expected to Reach USD 2.1 Billion Globally in 2018: Transparency Market Research
5. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
6. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
7. Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
8. Intellect Neurosciences Adds Two New Tau Programs to its Alzheimers Disease Development Pipeline
9. Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline
10. DuPont Leader Overviews 2012 Seed Research Pipeline with Investors
11. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):